Spyre Therapeutics Inc (SYRE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2014 | 12-2006 | |
| Cash Flows From Operating Activities | ||
| Net Income | -10,347 | N/A |
| Depreciation Amortization | 19 | N/A |
| Accounts payable and accrued liabilities | -165 | N/A |
| Other Working Capital | 26 | N/A |
| Other Operating Activity | 3,132 | 0 |
| Operating Cash Flow | $-7,335 | $N/A |
| Cash Flows From Investing Activities | ||
| PPE Investments | -181 | N/A |
| Other Investing Activity | -40 | 0 |
| Investing Cash Flow | $-221 | $N/A |
| Cash Flows From Financing Activities | ||
| Other Financing Activity | 5,575 | 0 |
| Financing Cash Flow | $5,575 | $N/A |
| Beginning Cash Position | 4,597 | N/A |
| End Cash Position | 2,616 | N/A |
| Net Cash Flow | $-1,981 | $N/A |
| Free Cash Flow | ||
| Operating Cash Flow | -7,335 | N/A |
| Capital Expenditure | -181 | N/A |
| Free Cash Flow | -7,516 | 0 |